Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme

European Journal of Medicinal Chemistry

Volumn 105, Issue , 2015, Pages 274-288

  Sestito, Simona ^a   Nesi, Giulia ^a   Daniele, Simona ^a   Martelli, Alma ^a   Digiacomo, Maria ^a   Borghini, Alice ^b   Pietra, Daniele ^b   Calderone, Vincenzo ^a   Lapucci, Annalina ^a   Falasca, Marco ^c   Parrella, Paola ^d   Notarangelo, Angelantonio ^d   Breschi, Maria C ^a   Macchia, Marco ^a   Martini, Claudia ^a   Rapposelli, Simona ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Alidans Srl   (Italy)

^c CURTIN UNIVERSITY   (Australia)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

GBM stem cells; Glioblastoma; Kinase inhibitors; Multi target therapy; Oxindole derivatives; PDK1 inhibitors

Indexed keywords

1 [4 (METHYLTHIO)PHENYL] 3 (2 OXOINDOLIN 5 YL)UREA; 2 OXOINDOLINE 5 SULFONYL CHLORIDE; 2 [(3,4 DIMETHOXYBENZYL)AMINO] N (2 OXOINDOLIN 5 YL)ACETAMIDE; 2 [(3,4 DIMETHOXYBENZYL)AMINO] N [2 OXO 3 (THIOPHEN 2 YLMETHYLENE)INDOLIN 5 YL]ACETAMIDE; 2' CHLORO N (2 OXO 2,3 DIHYDRO 1H INDOL 5 YL)ACETAMIDE; 3 [1 (1H IMIDAZOL 5 YL)ETHYLIDENE] N (3,4 DIMETHOXYBENZYL) 2 OXOINDOLINE 5 SULFONAMIDE; 5 AMINO 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; INDOLIN 2 ONE; N (2 OXOINDOLIN 5 YL)METHANESULFONAMIDE; N (3,4 DIMETHOXYBENZYL) 2 OXO 3 (THIOPHEN 2 YLMETHYLENE)INDOLINE 5 SULFONAMIDE; N (3,4 DIMETHOXYBENZYL) 2 OXOINDOLINE 5 SULFONAMIDE; N (3,4 DIMETHOXYBENZYL) 3 [(1 METHYL 1H IMIDAZOL 2YL)METHYLENE] 2 OXOINDOLINE 5 SULFONAMIDE; N [2 OXO 3 (THIOPHEN 2 YLMETHYLENE)INDOLIN 5 YL]METHANESULFONAMIDE; N [2 OXO 3 [(1H IMIDAZOL 5 YL)METHYLENE]INDOLIN 5 YL]METHANESULFONAMIDE; N [2 OXO [3 (1 METHYL 1H IMIDAZOL 2 YL)METHYLENE]INDOLIN 5 YL]METHANESULFONAMIDE; N [4 (METHYLSULFONYL)PHENYL] N' [2 OXO 3 (THIOPHEN 2 YLMETHYLENE)INDOLIN 5 YL]UREA; N [4 (METHYLSULFONYL)PHENYL] N' [2 OXO 3 [(1 METHYL 1H IMIDAZOL 2 YL]METHYLENE)INDOLIN 5 YL]UREA; N [4 (METHYLSULFONYL)PHENYL] N' [2 OXO 3 [(1H IMIDAZOL 5 YL)METHYLENE]INDOLIN 5 YL]UREA; N [4 (METHYLTHIO)PHENYL] N' [2 OXO 3 (THIOPHEN 2 YLMETHYLENE)INDOLIN 5 YL]UREA; N [4 (METHYLTHIO)PHENYL] N' [2 OXO [3 (1 METHYL 1H IMIDAZOL 2 YL)METHYLENE]INDOLIN 5 YL]UREA; N [4 (METHYLTHIO)PHENYL] N' [2 OXO [3 (1H IMIDAZOL 5 YL)METHYLENE]INDOLIN 5 YL]UREA; OXINDOLE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; 2-OXINDOLE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CELL COUNT; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

CELL COUNT; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; GLIOBLASTOMA; HUMANS; INDOLES; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84944897843     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.10.020     Document Type: Article

References (34)

1. T.A. Wilson, M.A. Karajannis, D.H. Harter, Glioblastoma multiforme: state of the art and future therapeutics, Surg. Neurol. Int. 5 (2014) 64.
2. P. Kleihues, W. Cavanee, World Health Organization Classification of Tumors: Pathology and Genetic: Tumors of the Nervous System, IARC, Press, 2000 (Ref Type: Generic).
3. A. Behin, et al., Primary brain tumours in adults, Lancet 361 (9354) (2003) 323-331.
4. R. Stupp, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol. 10 (5) (2009) 459-466.
5. S. Colak, J.P. Medema, Cancer stem cellseimportant players in tumor therapy resistance, FEBS J. 281 (21) (2014) 4779-4791.
6. A. Eramo, et al., Chemotherapy resistance of glioblastoma stem cells, Cell Death Differ. 13 (7) (2006) 1238-1241.
7. S. Bao, et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature 444 (7120) (2006) 756-760.
8. A. Shervington, C. Lu, Expression of multidrug resistance genes in normal and cancer stem cells, Cancer Investig. 26 (5) (2008) 535-542.
9. D. Chen, et al., Discovery of potent N-(isoxazol-5-yl) amides as HSP90 inhibitors, Eur. J. Med. Chem. 87 (2014) 765-781.
10. I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-kinaseeAKT pathway in human cancer, Nat. Rev. Cancer 2 (7) (2002) 489-501.
11. P.Y. Wen, et al., Current clinical development of PI3K pathway inhibitors in glioblastoma, Neuro-oncology 14 (7) (2012) 819-829.
12. K. Shih, et al., Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors, in: ASCO Meeting Abstracts, 2013.
13. X. Ma, Y. Hu, Targeting PI3K/Akt/mTOR cascade: the medicinal potential, updated research highlights and challenges ahead, Curr. Med. Chem. 20 (24) (2013) 2991-3010.
14. G. Nesi, et al., Synthesis of novel 3,5-disubstituted-2-oxindole derivatives as antitumor agents against human nonsmall cell lung cancer, ACS Med. Chem. Lett. 4 (12) (2013) 1137-1141.
15. M.D.M. AbdulHameed, et al., Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1, J. Chem. Inf. Model. 48 (9) (2008) 1760-1772.
16. I. Islam, et al., Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity, Bioorg. Med. Chem. Lett. 17 (14) (2007) 3814-3818.
17. I. Islam, et al., Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517, Bioorg. Med. Chem. Lett. 17 (14) (2007) 3819-3825.
18. A. Notarangelo, et al., Establishment and genetic characterization of ANGMCSS, a novel, immortal cell line derived from a human glioblastoma multiforme, Int. J. Oncol. 44 (3) (2014) 717-724.
19. S. Daniele, et al., Combined inhibition of AKT/mTOR and MDM2 enhances glioblastoma multiforme cell apoptosis and differentiation of cancer stem cells, Sci. Rep. 5 (2015).
20. C.W. Yap, PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem. 32 (7) (2011) 1466-1474.
21. I.V. Tetko, et al., Virtual computational chemistry laboratoryedesign and description, J. Computer-aided Mol. Des. 19 (6) (2005) 453-463.
22. T.T. Wager, et al., Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties, ACS Chem. Neurosci. 1 (6) (2010) 435-449.
23. D.E. Clark, In silico prediction of bloodebrain barrier permeation, Drug Discov. Today 8 (20) (2003) 927-933.
24. L. Sun, et al., Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl) methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases, J. Med. Chem. 42 (25) (1999) 5120-5130.
25. L. Sun, et al., Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases, J. Med. Chem. 41 (14) (1998) 2588-2603.
26. T. Asano, et al., The PI 3-kinase/Akt signaling pathway is activated due to aberrant pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells, Oncogene 23 (53) (2004) 8571-8580.
27. I. Murtaza, et al., Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells, Cancer Res. 69 (3) (2009) 1156-1165.
28. E.A. Jares-Erijman, T.M. Jovin, FRET imaging, Nat. Biotechnol. 21 (11) (2003) 1387-1395.
29. M. Verreault, et al., Combined RNAi-mediated suppression of rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model, PloS One 8 (3) (2013) e59597.
30. K. Nagashima, et al., Genetic and pharmacological inhibition of PDK1 in cancer cells characterization of a selective allosteric kinase inhibitor, J. Biol. Chem. 286 (8) (2011) 6433-6448.
31. S. Korur, et al., GSK3β regulates differentiation and growth arrest in glioblastoma, PloS One 4 (10) (2009) e7443.
32. M. Signore, et al., Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo, Cell Death Dis. 5 (2013) e1223-e1223.
33. S. Daniele, et al., Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy, Cell Death Dis. 5 (11) (2014) e1539.
34. S. Daniele, et al., Apoptosis therapy in cancer: the first single-molecule coactivating p53 and the translocator protein in glioblastoma, Sci. Rep. 4 (2014).